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Objective. The objective of this analysis was to compare clinical and cost outcomes associated with patients who had suspected
or documented methicillin-resistant Staphylococcus aureus (MRSA) infections treated with daptomycin, vancomycin, or linezolid
in complicated skin and skin structure infections (cSSSIs). Design. This was a retrospective analysis conducted from February to
June of 2007. Appropriate data was collected, collated, and subsequently evaluated with the purpose of quantifying length of stay,
antibiotic therapy duration, clinical cure rates, adverse drug events, and cost of hospitalization. Results. All 82 patients included
in the analysis experienced clinical cure. The duration of antibiotic therapy was similar among the three groups yet the length
of hospitalization was slightly shorter in the daptomycin group. Conclusions. The incidence of resistant staphylococcal infections
is increasing; therefore, judicious use of MRSA active agents is paramount. Future studies are necessary to determine if MRSA
treatment options can be stratiﬁed based on the severity of the infectious process.
1.Introduction
Skin and skin structure infections (SSSIs) are common
within the hospital setting as well as in the community.
SomecommonexamplesofSSSIsincludeabscesses,cellulitis,
diabetic foot infections, and surgical site infections. Oral
antibiotics can often be used to safely manage many SSSIs;
however, complicated SSSIs (cSSSIs) may be life threatening
and often involve deeper layers of skin and more severe
symptoms which will often necessitate hospitalization, intra-
venous antibiotics, and may also require surgical interven-
tion.
Although a variety of gram-positive and gram-negative
pathogens may cause SSSIs, methicillin-resistant Staphylo-
coccus aureus (MRSA) has emerged as the most common
pathogen [1, 2] A study of 265 community hospitals in the
Southeastern United States found the prevalence of MRSA as
the causative pathogen for surgical site infections increased
from 0.12 infections per 100 procedures to 0.23 infections
per 100 procedures from 2000 to 2005 [3] In addition, a
retrospectiveanalysisof288patientsmanagedwithoperative
debridement for SSSIs found that the incidence of MRSA
increased from 34 percent to 77 percent from 2000 to 2006.
Thepe r c e ntageo fMRSAisolat eswithanMIC≤0.5mcg/mL
to vancomycin decreased from 100 percent in 2000 to 62
percent in 2006 [4]. This increasing prevalence of MRSA
infection within the hospital and the community further
complicates the treatment of SSSIs as MRSA infections are
also known to be associated with an increased incidence of
bacteremia, septic shock, amputation and overall mortality
[5].
This increasing trend of resistance has not only been
noted within the realm of SSSIs but similar trends have been
observedforMRSAingeneral.DatacollectedbytheNational2 Journal of Pathogens
Nosocomial Infections Surveillance System showed that the
percentage of MRSA isolates in intensive care units increased
from 36 percent in 1992 to 64 percent in 2003 [6]. The
economic impact associated with the increasing number of
total MRSA infections is vast, and these resistant infections
are well established as prolonging hospital length of stay and
increasing total healthcare costs [5, 7, 8]. This impact is not
a new phenomena considering that epidemiologic data as far
back as the 1980s show that the mean length of stay (LOS)
associated with MRSA infection is about twice as long as that
for methicillin-susceptible S. aureus (MSSA) infection [5]
The cost of hospitalization for a patient with infections due
to MRSA is 2.5 times more than for patients with infections
caused by MSSA [7]. Recent data has also provided similar
observations as Engemann noted a higher 90-day mortality
rate (odds ratio 3.4) compared with MSSA in patients with a
surgical site infection caused by MRSA [8].
The economic impact of hospitalization is a major
concern; however, this is not the only burden when dis-
cussing MRSA infection. Reports of decreased susceptibility
of S. aureus, including MRSA, to vancomycin (Vancocin—
Eli Lilly), and also the associated mortality and cost con-
sequences of resistance, highlight the need for alternative
antibiotics [9, 10]. One such alternative agent, daptomycin
(Cubicin—Cubist), was approved by the US Food and
Drug Administration (FDA) in September 2003 for the
treatment of cSSSIs infections due to susceptible strains of
S. aureus (including MRSA), S. pyogenes, S. agalactiae, S.
dysgalactiae subspecies Equisimilis and Enterococcus faecalis
(vancomycin-susceptible strains only). Another alternative
agent, linezolid (Zyvox - Pﬁzer), was approved by the FDA
in 2000 for the treatment of patients with infections caused
by vancomycin-resistant Enterococcus faecium (VREF) or
methicillin-resistant Staphylococcus aureus (MRSA).
2.Objective
The objective of this analysis was to compare clinical and
cost outcomes of patients who had suspected or documented
MRSA cSSSIs treated with daptomycin, vancomycin, or
linezolid. Moreover, this study compared hospital lengths of
stay between these three therapeutic options.
3. Methods
This retrospective analysis was conducted from February
to June 2007 and took place at Huntsville Hospital, an
881-bed level 1 trauma and regional referral center located
in Northeast Alabama. No external funding was sought
for this analysis. Review of medical records of hospitalized
patients with cSSSIs that were treated with vancomycin,
linezolid,ordaptomycinwasperformedafterapprovalbythe
Institutional Review Board. Eligible patients included adults
aged17yearsorgreaterwithriskfactorsforMRSAinfections
who were admitted to the hospital with a clinical diagno-
sis of cSSSIs deﬁned as cellulitis, skin abscess, decubitus
ulcer, infected amputation stump, or surgical site infection.
Patients were excluded from the analysis if they exhibited
any of the following characteristics: pneumonia, bacteremia,
endocarditis, osteomyelitis, patients with MRSA MIC’s to
vancomycin of ≥2mcg/mL (at the time of study completion
this institution had no MICs ≥2) or documented resis-
tance to daptomycin or linezolid, patients with prosthetic
valves, patients with a vancomycin, daptomycin, or linezolid
allergy, or pregnant, lactating, neutropenic, or HIV-infected
patients. Antibiotic therapy was left to the discretion of the
prescribing physician; however, this choice could have been
inﬂuenced by the presence of a criterion for linezolid use at
this institution. Incision and drainage and/or debridement
were not performed on these patients as this is consistent
with previous cSSSIs trials previously completed [11, 12].
Data collected included gender, age, weight, antibiotic
allergies, dialysis status, hospital length of stay, additional
therapies, and microbiological culture and susceptibility
results. Antibiotic therapy data collected included antibiotic,
dose,route,frequency,indication,andtotalnumberofdoses.
Pertinent lab data collected included complete blood cell
count and basic metabolic panel or complete metabolic
panel.
Theprimarystudyendpointswere:durationofantibiotic
therapy,totalhospitallengthofstay,totalstayintheintensive
care unit, total cost of hospitalization for each patient,
and antibiotic-associated adverse reactions and adverse drug
events.
None of the study endpoints were stratiﬁed by pathogen
as the only pathogen providing a positive culture result in
these patients was MRSA seen in 10/26 in the daptomycin
group, 8/28 in the vancomycin group, and 8/28 in the
linezolid group. Patients were captured based on CPT code
for cellulitis, abscess, decubitus ulcer, infected amputation
stump or surgical site infection and were treated based on
suspected or documented MRSA infection. While only 26/82
patients actually had a positive culture for MRSA, each
patient had risk factors for MRSA infection and no other
organisms were identiﬁed from these cultures.
The average dose for daptomycin was 576mg per
day; linezolid was 1200mg per day; and vancomycin was
2430mg per day in order to achieve targeted vancomycin
troughs of 15–20mg/dL. The vancomycin, daptomycin,
and linezolid therapies were discontinued based on clinical
cure/improvement represented by the patient being afebrile
with a WBC ≤ 10,000/mm3, no bandemia, and a visibly
resolved cSSSIs noted by the physician. Patient’s must also
have meet criteria for hospital discharge and completed their
course of IV antibiotics while hospitalized. Patients could
be discharged with or without oral antimicrobial therapy.
Repeatbloodculturesattheendoftherapywerenotcollected
to determine microbiological cure as all patients met the
endpoint described as clinical cure. Adverse drug events
weredeterminedbyphysicians,nurses,andpharmacists.The
NaranjoscorewascalculatedforeachprobableADR[13,14].
4. Results
A total of 82 patients were included in this analysis with
26 receiving daptomycin, 28 vancomycin, and 28 linezolid.Journal of Pathogens 3
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Figure 1: Mean duration of antibiotic therapy.
Fifty-seven percent of patients were male and the mean age
ranged from 54 years (vancomycin) to 60 years (linezolid).
Thirty-two percent (26/82) of the evaluated patients had a
culture positive for MRSA and a slight majority, 38 percent
(10/26) were in the daptomycin group. Cellulitis was the
most common infection in each group and accounted for
67 percent of all infections. All patients included in this
analysis were discharged from the hospital and achieved
clinical cure/improvement per the guidelines above.
Figure 1 displays the duration of antibiotic therapy
results. The mean duration of antibiotic therapy was similar
among the three groups, ranging from 5.93 days for linezolid
to 6.21 days for vancomycin to 6.34 days for daptomycin.
However, the mean number of antibiotic doses varied signif-
icantly among the three groups. The daptomycin group had
the fewest mean number of doses with 5.5 doses, followed
by vancomycin with 8.1 doses, and linezolid with 11.1 doses.
DaptomycinisdosedoncedailyorifCrCl<30mL/minevery
48 hours, vancomycin dosing is dependent upon and varies
based on renal function, and linezolid dosing is standardized
to every 12 hours regardless renal function. Based on these
dosing regimens, the result regarding mean number of doses
would be expected. Additionally, of the 28 patients in the
linezolid group, there were a total of 128 intravenous (IV)
therapy days and 38 oral (PO) therapy days. A total of ﬁve
patients were switched from IV to PO during the course of
linezolid therapy.
Figure 2 portrays the length of hospitalization results.
Mean length of hospitalization was shortest in the van-
comycin group at 12.3 days compared with 12.9 days
and 15.7 days for the daptomycin and linezolid groups,
respectively. Length of stay on the ward and ICU was also
compared between the agents. Length of stay on the ward
was shortest for the daptomycin group at 10.6 days followed
by the vancomycin group at 11.2 days and then the linezolid
group at 12.4 days. Length of stay in the ICU was shortest for
the vancomycin group at 0.9 days followed by daptomycin at
2 days and lastly linezolid at 3.4 days.
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Figure 2: Mean length of hospitalization.
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Figure 3: Cost of therapy.
Cost of therapy is portrayed in Figure 3. The mean total
cost of therapy per patient was $4703.57 for vancomycin,
$5364.48 for daptomycin, and $6384.79 for linezolid. Drug
acquisition and administration costs, including drug levels
for vancomycin, were $123.78 for vancomycin, $1017.17 for
daptomycin, and $872.29 for linezolid. Hospital ward costs
for vancomycin, daptomycin, and linezolid were $3904.04,
$2749.19, and $3192.57, respectively, while ICU costs were
$675.75, $1598.12, and $2319.93, respectively.4 Journal of Pathogens
Table 1: Demographics.
Daptomycin Vancomycin Linezolid
(n = 26) (n = 28) (n = 28)
Gender
Female 14 7 14
Male 12 21 14
Age (years)
Mean 59 54 60
Range 18–88 17–86 19–93
Positive culture for MRSA 10 8 8
Infection type
Cellulitis 16 21 18
Decubitus ulcer 6 3 0
Abscess 2 4 9
Surgical site 2 0 1
Values are presented as n.
MRSA: Methicillin-resistant Staphylococcus aureus.
No patients treated with daptomycin or linezolid expe-
rienced an antibiotic-associated adverse drug event (ADE).
OnepatientinthevancomycingroupexperiencedRed-man’s
syndrome after the ﬁrst dose of vancomycin requiring an
additional medication (diphenhydramine 25mg IVP X 1
dose) to treat this adverse drug reaction (ADR). The cost of
this additional medication was nominal at $0.25 yet was still
added into the cost of the vancomycin therapy. The Naranjo
scorewascalculatedasa7designatingtheeventasaprobable
adverse drug reaction [13, 14]. The patient was continued on
the vancomycin therapy yet the infusion rate was slowed to
not exceed 1 gram per hour per the recommendations in the
package insert.
5. Discussion
The principle causative pathogen in cSSSIs, MRSA, has
become well known. This multi-drug resistant organism is
associated with a signiﬁcant impact on morbidity, mortality,
length of hospitalization, and cost of care. In the present
study, MRSA was responsible for 26/82 (32 percent) of
cSSSIs, however, each patient had risk factors for MRSA
infection and no other organisms were identiﬁed. This is
lower than the 77 percent in 2006 reported by Awad et
al.; however, this may reﬂect a generally sicker population
in that study since patients required surgical debridement
for their cSSSIs [4]. Further complicating this picture is
the recent emergence of MRSA with decreased susceptibility
to vancomycin, further justifying the potential demand for
alternative antimicrobial agents [15]. Two such alternative
agentsarelinezolidanddaptomycinwhichbothoﬀerspeciﬁc
therapeuticadvantagesovervancomycinincertaininfectious
processes.
A primary objective of this study was to assess patient
outcomesandtheassociatedcostsrelatedtodrugacquisition,
administration, and per diem hospital costs for daptomycin
compared with vancomycin and linezolid. The mean total
cost for daptomycin therapy was intermediate between
vancomycin and linezolid due to the decreased cost for
the patient hospital stay on the ward associated with
daptomycin compared with vancomycin and linezolid which
countered the increased acquisition cost of the drug. All
agents evaluated were also associated with a similar and a
relatively short duration of antibiotic therapy in the present
study. The duration noted in this analysis was shorter than
that recommended in the package inserts of each respective
agent for cSSSIs. Length of hospital stay was also compared
and found to be similar in the daptomycin and vancomycin
groups, while longer in the linezolid group. This ﬁnding
is interesting considering the oral availability of linezolid
and the ability to transition to the oral equivalent with
this agent. Shorter length of intensive care unit stay in the
vancomycin group contributed to the overall lower cost of
drug therapy compared with daptomycin and linezolid. In
the present study, clinical cure/improvement documented
post treatment was represented by the patient being afebrile
with a WBC < 10,000 with no bandemia and a visibly
resolved cSSSIs. All patients in this study met the deﬁnition
for clinical cure/improvement.
Other studies to investigate these therapeutic alternatives
in cSSSIs were found using an English-language Medline
search. Weigelt [16] and colleagues describe a study in which
1180 patients with a cSSSIs were treated with linezolid
600mg IVPB and PO or vancomycin 1 gram IVPB every 12
hours. Duration of treatment with linezolid was 11.8 days
and was longer than that of vancomycin at 10.9 days; P<
.004. Duration of IV treatment was also shorter for linezolid
(4 versus 9 days; P<. 0001). No signiﬁcant diﬀerence was
found between the clinical cure rates between linezolid (92.2
percent) versus vancomycin (88.5 percent). Modiﬁed intent
to treat microbiologic cure of MRSA of linezolid was 71
percent and vancomycin was 55.1 percent (P = .002). MSSA
microbiological cure was found to be 73 percent versus 66.4
percent (P = .264) [16].
Itani describes the health outcomes resulting from this
large study as well as duration of IV treatment and weekly
discharges [17]. With regards to the ITT population, the
mean initial LOS was signiﬁcantly shorter in the linezolid
a r m( 6 . 7d a y sv e r s u s9 . 4d a y s ,P<. 01). Following initial
hospitalization, more patients receiving linezolid were dis-
charged from the hospital than those receiving vancomycin
(P<. 0001). The rates of infection-related readmission
between the two groups was comparable for all study
populations (P>. 05) and ﬁnally, fewer IV antibioitic
treatment days were needed in patients receiving linezolid
compared with those receiving vancomycin (P<. 0001) [17].
Another evaluation of this data among United States
subjects also found clinical and cost advantages for patients
treated with linezolid [18]. Mean cost for ITT population
patients treated with linezolid versus vancomycin was $4865
versus $5738, respectively, (P = .017), and in the MRSA
population speciﬁcally the cost was $4481 versus $6006 for
linezolid and vancomycin, respectively (P = .041). Total
costs in this study included all costs incurred by the patients
during hospitalization and following discharge [18].
Stevens and colleagues [19] published a study of 460
patients with presumed SSSIs MRSA infection that wereJournal of Pathogens 5
randomized to linezolid 600mg IVPB/PO or vancomycin 1
gram IVPB every 12 hours for 7 days or longer. Clinical cure
(intenttotreat)was64.6percentinthelinezolidgroupversus
62.1 percent in the vancomycin group and 69.8 percent
and 74.4 percent, respectively, (P value not provided) when
looking only at patients with MRSA [19].
Previous trials have also shown daptomycin to be
clinically eﬃcacious and exhibits a trend toward positive
economic outcomes when compared to vancomycin. Speciﬁ-
cally, daptomycin was shown to provide a more rapid clinical
response than vancomycin in an open-label study of 265
patients with cSSSIs [11]. Additionally, hospital costs were
noted to be signiﬁcantly lower in the daptomycin group in
this study as patients in the daptomycin group were found
on average to need 3 days less of antimicrobial therapy and a
signiﬁcantlyhigherproportionofpatientsachievedcomplete
resolution of their infections. Other clinical trial data show
a trend toward decreased time to resolution of symptoms
with 63% of daptomycin-treated patients and 33% of the
comparator group requiring only 4–7 days of therapy [11].
In addition to these ﬁndings, In vitro and animal data seem
to indicate that daptomycin is rapidly bactericidal when
compared with vancomycin [11].
The eﬃcacy and safety of daptomycin in cSSSIs was
demonstrated in 2 clinical trials involving a total of 1092
patients. Daptomycin 4mg/kg IVPB every 24 hours for 7–
14 days was compared with penicillinase-resistant penicillins
4–12grams IVPB per day or vancomycin 1 gram IVPB every
12 hours and clinical success was achieved in 83.4 percent
and84.2percentofthedaptomycinandcomparatorpatients.
Clinical success was achieved in 85.9 percent and 87 percent,
respectively, of those infected with MSSA at baseline, while
clinical success was achieved in 75 percent and 69.4 percent,
respectively, of those infected with MRSA at baseline. The
frequency and distribution of adverse events were similar
among both treatment groups in these trials [12].
Limitations of the present analysis include the retrospec-
tive method in which it was performed, prohibiting a deﬁni-
tive conclusion regarding causality. Additionally, the clinical
eﬀectivenessofvancomycinwaslessdeﬁnedduringthestudy
period with regard to the developing data describing an
MRSA MIC creep to this agent. Furthermore, at the time in
which the study was conducted, the institutions Pharmacy
and Therapeutics Committee positioned vancomycin as the
ﬁrst-line agent for cSSSIs ahead of daptomycin and linezolid
astoallowvancomycintoserveasthemostcommonempiric
therapy resulting in patients having received vancomycin
prior to receiving alternate agents such as daptomycin and
linezolid.
6. Conclusion
The incidence of resistant staphylococcal infections is
increasing; therefore, the judicious use of antibiotics, such as
daptomycin, linezolid, and vancomycin, with good activity
against MRSA, is paramount. This study showed similar
clinical and cost outcomes with the use of daptomycin when
compared with vancomycin and linezolid in cSSSIs for a
similar patient population. In addition, while daptomycin
showed a slightly greater overall duration of therapy it
was well tolerated and showed an overall decreased length
of stay in the ward comparatively which proved to be
ﬁnancially advantageous considering that per diem hospital
costs accounts were the most expensive healthcare resource
in this study population. The retrospective design of this
analysis further justiﬁes the conclusion that future studies
are necessary to determine if MRSA treatment options can
be stratiﬁed based on the severity of the infectious process
as to ensure that the duration of a patient’s hospitalization is
optimized.
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